AJP - Heart Ad Instruments
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Heart Circ Physiol 285: H1220-H1228, 2003. First published May 22, 2003; doi:10.1152/ajpheart.00076.2003
0363-6135/03 $5.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
285/3/H1220    most recent
00076.2003v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (8)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pyle, W. G.
Right arrow Articles by Hofmann, P. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pyle, W. G.
Right arrow Articles by Hofmann, P. A.

Cardioprotection through a PKC-dependent decrease in myofilament ATPase

W. Glen Pyle, Yi Chen, and Polly A. Hofmann

Department of Physiology, University of Tennessee, Memphis, Tennessee 38163

Submitted 24 January 2003 ; accepted in final form 21 May 2003

Activation of myocardial {kappa}-opioid receptor-protein kinase C (PKC) pathways may improve postischemic contractile function through a myofilament reduction in ATP utilization. To test this, we first examined the effects of PKC inhibitors on {kappa}-opioid receptor-dependent cardioprotection. The {kappa}-opioid receptor agonist U50,488H (U50) increased postischemic left ventricular developed pressure and reduced postischemic end-diastolic pressure compared with controls. PKC inhibitors abolished the cardioprotective effects of U50. To determine whether {kappa}-opioid-PKC-dependent decreases in Ca2+-dependent actomyosin Mg2+-ATPase could account for cardioprotection, we subjected hearts to three separate actomyosin ATPase-lowering protocols. We observed that moderate decreases in myofibrillar ATPase were equally cardioprotective as {kappa}-opioid receptor stimulation. Immunoblot analysis and confocal microscopy revealed a {kappa}-opioid-induced increase in myofilament-associated PKC-{epsilon}, and myofibrillar Ca2+-independent PKC activity was increased after {kappa}-opioid stimulation. This PKC-myofilament association led to an increase in troponin I and C-protein phosphorylation. Thus we propose PKC-{epsilon} activation and translocation to the myofilaments causes a decrease in actomyosin ATPase, which contributes to the {kappa}-opioid receptor-dependent cardioprotective mechanism.

U50,488H; Western blot; confocal microscopy; protein kinase C activity; left ventricular developed pressure; {kappa}-opioid



Address for reprint requests and other correspondence: P. A. Hofmann, Dept. of Physiology, Univ. of Tennessee, Memphis, 894 Union Ave., Memphis, TN 38163 (E-mail: phofmann{at}physio1.utmem.edu).




This article has been cited by other articles:


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
E. E. Shaw, P. Wood, J. Kulpa, F. H. Yang, A. J. Summerlee, and W. G. Pyle
Relaxin alters cardiac myofilament function through a PKC-dependent pathway
Am J Physiol Heart Circ Physiol, July 1, 2009; 297(1): H29 - H36.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
B. C. Blunt, Y. Chen, J. D. Potter, and P. A. Hofmann
Modest actomyosin energy conservation increases myocardial postischemic function
Am J Physiol Heart Circ Physiol, March 1, 2005; 288(3): H1088 - H1096.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2003 by the American Physiological Society.